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Background
Pyruvate, as an end-product of glycolysis, might influence
the electrophysiological parameters of the heart by several
mechanisms: Pyruvate enhances the phosphorylating
potency of the cytosol; it can facilitate the reduction of
inorganic phosphate and finally can influence the cyto-
plasamatic redox state by decreasing the H+ concentration.
According to the literature, pyruvate enhances the ampli-
tude of the action potential (APA) and also reduces the
duration of the action potential (APD); hereby, it might
be used to enhance the contractility in case of heart fail-
ure. Our aim was to determine the electrophysiological
and hemodynamical effects of pyruvate on diabetic and
control rat hearts.
Methods
Using conventional microelectrode techniques and the
Langendorff system we examined the effects of sodium
pyruvate (1, 3, 10 and 30 mmol/L) on electrophysiologi-
cal and hemodynamic parameters of control (n = 28) and
streptozotocin-induced diabetic (n = 29) rat hearts.
Results
Similarly to our previous electrophysiological results, the
APD of the right ventricular papillary muscles of diabetic
rats' hearts was significantly longer compared to the con-
trol animals. In the control group only the highest pyru-
vate concentration caused significant APD reduction
while in the diabetic groups the second and third pyruvate
concentrations already significantly reduced the APD. In
our Langendorff system both the mean left ventricular
pressure (LVP) and the diastolic left ventricular pressure
(LVPD) were significantly higher in the control group.
Pyruvate treatment induced significant increase only in
the control group (LVPD at 3, 10 and 30 mmol/L pyruvate;
LVP at 10 and 30 mmol/L pyruvate).
Conclusion
Our electrophysiological result mainly correlates with the
previously published results. Corresponding to our hemo-
dynamic results we can conclude that in case of diabetic
animals higher pyruvate concentrations would be
required to achieve the same favorable effect. On account
of its beneficial effect on the heart muscle, pyruvate can
become a potential drug in the future, one which can
open new possibilities in the therapy of cardiogenic
shock.
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